News

CMU Professor Su-Hang Zhuo’s Research Team Honored the “2018 Future Technology Award” by Developing the World's First Nucleic Acid Interference Drug for Myopia Treatment

Date: October 19, 2018

CMU professor Su-Hang Zhuo’s research team developed the world’s first nucleic acid interference drug which can prevent the deterioration of myopia. The development is a breakthrough in the field of myopia treatment. Professor Zhuo’s team was honored the “2018 Future Technology Award” as a praise for their great contribution.

Myopia is the most common eye disease. Nowadays we generally focus on the ways to deal with eyesight instead of improving it. There is a lack of appropriate method to prevent eyesight from deteriorate. Thus, professor Su-Hang Zhuo’s research team dedicated themselves to developing the world’s first nucleic acid interference drug. The drug turned out better than the only existing drug “Atropine” that can cure myopia; moreover, no side effect or toxicity is found in this nucleic acid interference drug.

By doing cooperation with biotechnology company, professor Zhuo’s team had completed the manufacture of the drug and the eye drop, and they have filed the application for global patent. With the support of the government’s “Industrial Value Creation Program for Academia”, professor Zhuo’s team had completed the projects required for pre-clinical test. It is expected that a company for new drug development will be established next year and the clinical trials on human subjects will start from 2019. We can expect there will be a breakthrough in the advance of myopia treatment.

【Photos】

Professor Su-Hang Zhuo
           

 

TOP